Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise Life Science Investing
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis with Its Novel Bispecific Antibody ATI-052 Life Science Investing
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate Life Science Investing
Summit Therapeutics Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC Life Science Investing
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Life Science Investing
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Life Science Investing
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Life Science Investing
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 Life Science Investing
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Life Science Investing
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 Life Science Investing
